| Without naming the group, Naveen Kulkarni, CEO Polyclone Bioservices, said, "Presently, we are in talks with a US investment group and expect to sign-up shortly, say in a weeks time." |
| Polyclone, a small biotech enterprise established in 2005 with $0.5 million in bank debt and self-funded, has developed in-silico (performed on computer or via computer simulation) and core facility capabilities to offer research services comprising a mix of wet lab and informatics tools and technologies. |
| The company, in the last six months, has developed non-contact micro-array (is a collection of microscopic DNA spots) and stem cell array. |
| "Presently, we are in talks with a few Indian companies like Cryo Stem Cells, Manipal Group, All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR) for testing and validating these new products," said Kulkarni. |
| Recently, the company got recognition from the Department of Scientific and Industrial Research (DSIR) as a research and development (R&D) unit and is expected to enable the company to foray into research activities funded by the Department of Science and Technology (DST), Department of Biotechnology (DBT) and various other government initiatives, he added. |
| For revenues, Polyclone Bioservices has tied up with Eppendorf India to market its bioinformatics tool 'eprime'. |
| "eprime is polymer chain reaction (PCR)-based product which enables researchers to design-the-process and analyse genomic data, extensively used in the research/diagnostic market," explained Kulkarni. |
| "This product has been licensed to Eppendorf India to install as original equipment in selling lab apparatus in the domestic and global markets," he added. |
| The company is expected to sign 50 licences to 60 licences in India this year and earn about $100,000 in revenues globally. |
Top Section
Explore Business Standard